UK Markets close in 2 hrs 41 mins
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • FTSE 250

    23,574.62
    +140.55 (+0.60%)
     
  • AIM

    1,236.75
    -10.13 (-0.81%)
     
  • GBP/EUR

    1.1873
    +0.0006 (+0.05%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • BTC-GBP

    43,603.45
    +431.34 (+1.00%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • DOW

    35,870.95
    -60.10 (-0.17%)
     
  • GOLD FUTURES

    1,861.20
    -0.20 (-0.01%)
     
  • NIKKEI 225

    29,683.09
    +84.43 (+0.29%)
     
  • HANG SENG

    25,319.72
    -330.36 (-1.29%)
     
  • DAX

    16,221.73
    -29.40 (-0.18%)
     
  • CAC 40

    7,141.98
    -14.87 (-0.21%)
     

Biotest AG: Biotest increases sales by 9% in the first nine months 2021

  • Oops!
    Something went wrong.
    Please try again later.
·5-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DGAP-News: Biotest AG / Key word(s): Quarter Results
11.11.2021 / 09:00
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Biotest increases sales by 9% in the first nine months 2021

- Increase in plasma collection centres to 26 in Europe

- Final manufacturing authorization for expansion project Biotest Next Level granted

- Guidance confirmed


Dreieich, 11 November 2021. The Biotest Group recorded revenues of € 371.4 million in the first nine months of the financial year 2021 (same period of the previous year: € 341.6 million). This represents an increase of € 29.8 million or 8.7% over the figure for the same period of the previous year. In particular, sales of Biotest's immunoglobulin preparation Intratect(R) were significantly higher than in the previous year.

Earnings before interest and taxes (EBIT) for the first nine months of the financial year 2021 amounted to € -11.2 million (same period of the previous year: € - 7.8 million). This includes expenses for the Biotest Next Level project in the amount of € 57.5 million (same period of the previous year: € 59.3 million). The decline in EBIT compared to the previous year is the result of a disproportionate increase in manufacturing costs, especially with regard to plasma sourcing costs, and a low-margin country and product mix compared to the previous year.

Adjusted for expenses for the Biotest Next Level expansion project, adjusted EBIT in the first nine months of 2021 was € 46.3 million and thus, as in the previous year, clearly positive (same period of the previous year: € 51.6 million).

The Biotest Group's earnings after taxes (EAT) improved to € -28.3 million in the first three quarters of financial year 2021, compared to € -31.8 million in the same period of the previous year.

In the third quarter of 2021, Biotest continued with the expansion of its plasma collection capacity. In July 2021, the Hungarian health authority approved Biotest's eleventh plasmapheresis centre in Hungary. The centre is located in Sopron. Since mid-August 2021, all official approvals for Biotest's sixth plasmapheresis centre in the Czech Republic, located in Brno, have also been obtained. The Company is thus further increasing its plasma production capacities. In total, Biotest had 26 plasma collection centres in Europe at the end of the first nine months of 2021. The company plans to open additional centres in the future.

A partial acceptance inspection was carried out by the Darmstadt Regional Council in March 2021 in the Biotest Next Level expansion project, as part of the granting of the manufacturing authorisation in accordance with Section 13 of the German Medicinal Products Act. Final acceptance by the Darmstadt Regional Council took place at the beginning of July 2021. The focus was on the Process Performance Qualification (PPQ) batches, whose production was inspected on site by the Darmstadt Regional Council. The inspection was passed without any critical or serious deficiencies and in the course of this, the manufacturing authorisation was granted in accordance with Section 13 of the German Medicinal Products Act. The last of the Process Performance Qualification (PPQ) batches was successfully manufactured at the beginning of August 2021. With the achievement of this milestone, all data on production has been collected and is now being compiled as part of preparing the dossier.

Guidance:

For financial year 2021, the Board of Management expects revenue growth in the mid-single-digit percentage range. Earnings in 2021 will be influenced by various factors. Besides the expected expenses of €75 million to €85 million from the Biotest Next Level expansion project, including the associated research and development costs, the tense situation in the crisis regions, particularly in the Middle East and Asia, as well as the global impact of the COVID-19 pandemic, could also have an impact. Based on the aforementioned factors, the Board of Management expects EBIT to be between €-5 million and €-10 million.

The 2021 nine month report is available on the company's website at: https://www.biotest.com/de/en/investor_relations/news_and_publications/publications/quarterly_reports.cfm

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.


11.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Biotest AG

Landsteinerstraße 5

63303 Dreieich

Germany

Phone:

0 61 03 - 8 01-0

Fax:

0 61 03 - 8 01-150

E-mail:

investor_relations@biotest.de

Internet:

http://www.biotest.de

ISIN:

DE0005227235, DE0005227201

WKN:

522723, 522720

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1248048


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting